NCT05482893
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05482893
Title Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Acronym TWINPEAK
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Phanes Therapeutics
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.